Wall Street expects a year-over-year decline in earnings on lower revenues when Agios Pharmaceuticals (AGIO) reports results for the quarter ended December 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Fe ...

CAMBRIDGE, Mass., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 12, 2026, at 8:00 a.m. ET to report its fourth quarter and full year 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s websi ...

We came across a bullish thesis on Agios Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on AGIO. Agios Pharmaceuticals, Inc.'s share was trading at $27.80 as of January 15th. AGIO’s trailing and forward P/E were 3.54, respectively according to Yahoo Finance. I'll Play, Says Jim Cramer About Bristol-Myers (BMY) Photo by Myriam Zilles on Unsplash Agios Pharmaceuticals is a clinical-stage biotech company focused on cellular metabolism through oral, ...

PresentationOur next presenting company is Agios, and presenting on behalf of the company, we have CEO, Brian Goff. Brian, over to you.Welcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tess Romero, and I'm one of the senior biotech analysts here at JPMorgan.Brian GoffCEO & Director All right. Thank you, Tess, and good morning, everybody. It is great to be back at JPMorgan, and I'm really excited to share our outlook for 2026 and why we're so excited about the path forward for ...

Agios Pharmaceuticals (NasdaqGS:AGIO) FY Conference January 14, 2026 11:15 AM ET Company ParticipantsBrian Goff - CEOSarah Gheuens - CMO and Head of R&DTsveta Milanova - Chief Commercial OfficerConference Call ParticipantsTessa Romero - Senior Analyst and Biotechnology Equity ResearchTessa RomeroWelcome, everyone, to the 44th Annual JPMorgan Healthcare Conference. My name is Tessa Romero, and I'm one of the Senior Biotech Analysts here at JPMorgan. Our next presenting company is Agios, and presenting on beh ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Business Overview - Agios is positioned for growth and aims for profitability with its existing commercial portfolio[3, 4] - The company has a strong foundation in hematology and aspires to become a sustainable rare disease company[5] - Agios estimates a total global market size of over $10 billion by 2030 for its current pipeline indications[11] Product Pipeline and Approvals - AQVESME (mitapivat) is now approved in the U S for anemia in adults with alpha- or beta-thalassemia, addressing approximately 4,000 addressable patients at launch[7, 17, 23] - AQVESME has a potential to deliver $1 billion in global peak-year-sales across PKD and thalassemia indications[24] - Pyrukynd is approved in the U S , EU, and UK for Pyruvate Kinase Deficiency[7] Clinical Development - In Sickle Cell Disease, 40.6% of patients achieved Hemoglobin response (≥1 g/dL) in the mitapivat trial[37] - Phase 1 tebapivat data demonstrates a 1.2 g/dL increase (2mg) and 1.9 g/dL increase (5mg) in mean change from baseline in Hb across dosing cohorts at Day 28 in SCD patients[44] - In LR-MDS, 40% of low transfusion burden cohort achieved transfusion independence with tebapivat[51]

Core Insights - Agios Pharmaceuticals (AGIO) has outlined its strategic priorities for 2026, focusing on key milestones and commercial activities in the coming year [1] Group 1: Strategic Priorities - The U.S. commercial launch of AQVESME for thalassemia is underway following FDA approval in December 2025 [1] - A pre-sNDA meeting with the FDA for mitapivat in sickle cell disease is anticipated in the first quarter of 2026, with a planned U.S. regulatory submission to follow [1] Group 2: Pipeline Development - The company is advancing its early- and mid-stage pipeline across multiple high-value indications [1] Group 3: Financial Outlook - Agios Pharmaceuticals aims for a path to profitability through its existing commercial presence in thalassemia and PK deficiency, with the potential to achieve over $1 billion in peak global sales [1]

Core Insights - Agios Pharmaceuticals has outlined its strategic priorities and key milestones for 2026, focusing on the launch of AQVESME™ and expansion into additional indications for its PK activation franchise [1][3] Company Performance - In 2025, Agios achieved significant progress, highlighted by the U.S. approval of AQVESME™, the first medicine approved for treating anemia in adults with alpha- or beta-thalassemia [2][9] - The company aims to become a sustainable and diversified rare disease company, leveraging its existing commercial presence [2][3] 2026 Strategic Priorities - The company plans a high-impact U.S. launch of AQVESME in thalassemia and seeks to expand its PK activation franchise into sickle cell disease and lower-risk myelodysplastic syndromes [3][8] - Agios is committed to disciplined capital allocation and operational efficiency to support long-term sustainability [3] Anticipated Milestones - AQVESME's U.S. commercial launch is set for late January 2026, following FDA approval in December 2025 [9] - A pre-sNDA meeting with the FDA for mitapivat in sickle cell disease is anticipated in Q1 2026, with a regulatory submission to follow [8][9] - Topline results from the Phase 2b trial of tebapivat in lower-risk myelodysplastic syndromes are expected in the first half of 2026 [6][8] - Enrollment in the Phase 2 sickle cell disease trial of tebapivat was initiated in 2025, with topline results expected in the second half of 2026 [9] Pipeline Development - Agios is advancing its early- and mid-stage pipeline across multiple high-value indications, including a Phase 1 trial of AG-236 for polycythemia vera and a Phase 1b trial of AG-181 for phenylketonuria [10][11]

CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 8:15 a.m. PST / 11:15 a.m. EST. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under th ...